Fred Hutch Cell Therapy Lab

Seattle, WA
National Center
CAR-T Cell Therapy
529 confirmed programs · 68 sponsors · Last scored 2026-04-29
76.4
Signal Score
○ FDA Inspections ✓ Clinical Trials (529) ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Fred Hutch Cell Therapy Lab

Signal Score
76.4/100 (as of 2026-04-29)
Quality Compliance
Assessment pending
Headquarters
Seattle, WA
Modalities
CAR-T, Cell Therapy
Active Programs
529 confirmed from ClinicalTrials.gov across 68 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Fred Hutch Cell Therapy Lab

CDMO.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 97.8
529 active programs across 68 sponsors
Modalities: CAR-T, Cell Therapy
395 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
529 active programs across 68 sponsors · Modalities: CAR-T, Cell Therapy · 395 programs in advanced phases (Phase 2/3)
Programs 529
Sponsors68
ModalitiesCAR-T, Cell Therapy
529 active programs across 68 sponsors
Modalities: CAR-T, Cell Therapy
395 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT04579523 ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With... PHASE1 Not Yet Recruiting
NCT07194980 Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment... PHASE2 Recruiting
NCT05621291 A Study to Evaluate Next-Generation Sequencing (NGS) Testing... NA Recruiting
NCT07225985 Pralatrexate With Bendamustine and Total-Body Irradiation... PHASE1/PHASE2 Recruiting
NCT07228624 Ruxolitinib Before, During and After Hematopoietic Cell... PHASE2 Recruiting
NCT06983899 Exercise Training for the Improvement of Immune Activity and... NA Recruiting
NCT07227571 Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for... PHASE1 Recruiting
NCT07098364 ST-067 in Combination With CD19-Directed CAR T-Cell Therapy... PHASE1/PHASE2 Recruiting
NCT06817889 Remdesivir for the Treatment of Upper Respiratory Tract... PHASE2 Recruiting
NCT06947928 Placebo-Controlled Trial of IFx-Hu2.0 Followed By... PHASE2/PHASE3 Recruiting
View all 529 programs →
Source: ClinicalTrials.gov · Retrieved May 20, 2026
Financial Stability 68.0
Parent company: Fred Hutchinson Cancer Center
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Fred Hutchinson Cancer Center
Financial assessment: 68.0/100
Capacity 58.0
1 manufacturing site: Seattle, WA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: Seattle, WA
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
1 manufacturing site: Seattle, WA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100

Clinical Activity 529 studies

NCT04579523 ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With... PHASE1 Not Yet Recruiting NCT07194980 Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of... PHASE2 Recruiting NCT05621291 A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring... NA Recruiting NCT07225985 Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor... PHASE1/PHASE2 Recruiting NCT07228624 Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older... PHASE2 Recruiting NCT06983899 Exercise Training for the Improvement of Immune Activity and Treatment... NA Recruiting NCT07227571 Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of... PHASE1 Recruiting NCT07098364 ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in... PHASE1/PHASE2 Recruiting NCT06817889 Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV... PHASE2 Recruiting NCT06947928 Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In... PHASE2/PHASE3 Recruiting NCT07052630 Patient Navigation and the Planning Advance Care Together Website to Improve... NA Recruiting NCT07006727 Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing... PHASE1 Recruiting NCT07046078 Combination Chemotherapy (FLAG-Ida) Followed Immediately by... PHASE2 Recruiting NCT06752694 Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After... PHASE2 Recruiting NCT06928662 Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body... PHASE1/PHASE2 Recruiting NCT07164443 A Study of Pasritamig Versus Placebo in Late Line Metastatic... PHASE3 Recruiting NCT06839053 Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With... PHASE2 Recruiting NCT06094842 Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific... PHASE1 Withdrawn NCT05936229 Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR... PHASE1/PHASE2 Withdrawn NCT06609928 FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric... PHASE1 Recruiting
+ 509 more studies
Source: ClinicalTrials.gov · Retrieved May 20, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →

Similar CDMOs

Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 90.8
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 83.8
CAR-T, Cell Therapy
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 83.7
CAR-T, Cell Therapy, AAV
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.5
CAR-T, Cell Therapy